Key Insights

Highlights

Success Rate

85% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

5.1%

2 terminated out of 39 trials

Success Rate

84.6%

-1.9% vs benchmark

Late-Stage Pipeline

5%

2 trials in Phase 3/4

Results Transparency

36%

4 of 11 completed with results

Key Signals

4 with results85% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (6)
P 1 (9)
P 2 (5)
P 3 (2)

Trial Status

Recruiting19
Completed11
Active Not Recruiting3
Not Yet Recruiting3
Terminated2
Enrolling By Invitation1

Trial Success Rate

84.6%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (39)

Showing 20 of 20 trials
NCT07425574RecruitingPrimary

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

NCT07419334Phase 3RecruitingPrimary

Study of ALK-001 on the Progression of Stargardt Disease

NCT04545736Phase 1Recruiting

Oral Metformin for Treatment of ABCA4 Retinopathy

NCT07439887Phase 1RecruitingPrimary

Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

NCT07266584Not ApplicableRecruitingPrimary

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

NCT07502664Recruiting

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

NCT06445322RecruitingPrimary

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

NCT07161544Phase 1RecruitingPrimary

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

NCT07417566Phase 1RecruitingPrimary

A Study of DC6001 Tablet in Healthy Chinese Adult Subjects

NCT07298174Not Yet Recruiting

Wide Field OCTA in Ocular Diseases

NCT07265895Not Yet Recruiting

Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations

NCT06467344Phase 1RecruitingPrimary

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

NCT05956626Phase 2RecruitingPrimary

A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

NCT06319872Phase 1Recruiting

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

NCT06435000Recruiting

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

NCT06989658Not ApplicableNot Yet RecruitingPrimary

Feasibility and Tolerability Study of Smart Contact Lens With Healthy Subjects and Patients With Stargardt's Disease

NCT06591806RecruitingPrimary

An Observational Study in Children and Adults With Stargardt Disease

NCT06377150CompletedPrimary

ABCA4-associated Disease in Childhood and Adolescence - a Phenotype Study

NCT06942572Phase 1RecruitingPrimary

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

NCT02402660Phase 2Enrolling By InvitationPrimary

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Scroll to load more

Research Network

Activity Timeline